CL2014002062A1 - Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros. - Google Patents
Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros.Info
- Publication number
- CL2014002062A1 CL2014002062A1 CL2014002062A CL2014002062A CL2014002062A1 CL 2014002062 A1 CL2014002062 A1 CL 2014002062A1 CL 2014002062 A CL2014002062 A CL 2014002062A CL 2014002062 A CL2014002062 A CL 2014002062A CL 2014002062 A1 CL2014002062 A1 CL 2014002062A1
- Authority
- CL
- Chile
- Prior art keywords
- chemoprotect
- cdk19
- cortistatin
- cdk1
- dementias
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4739—Cyclin; Prad 1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Abstract
The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI -related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides meth
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261594023P | 2012-02-02 | 2012-02-02 | |
US201261673419P | 2012-07-19 | 2012-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014002062A1 true CL2014002062A1 (es) | 2015-03-20 |
Family
ID=47716178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014002062A CL2014002062A1 (es) | 2012-02-02 | 2014-08-01 | Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros. |
Country Status (16)
Country | Link |
---|---|
US (2) | US9321737B2 (es) |
EP (2) | EP3431087A1 (es) |
JP (1) | JP6193268B2 (es) |
KR (1) | KR20150023223A (es) |
CN (1) | CN104363913B (es) |
AU (1) | AU2013214783B2 (es) |
BR (1) | BR112014019052A8 (es) |
CL (1) | CL2014002062A1 (es) |
CO (1) | CO7151516A2 (es) |
EA (2) | EA028595B1 (es) |
GE (1) | GEP201706688B (es) |
MY (1) | MY165446A (es) |
PH (1) | PH12014501862A1 (es) |
SG (1) | SG11201404596UA (es) |
UA (1) | UA117342C2 (es) |
WO (1) | WO2013116786A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013295594B2 (en) | 2012-07-27 | 2018-03-29 | Biogen Ma Inc. | Compounds that are S1P modulating agents and/or ATX modulating agents |
JP2015533778A (ja) * | 2012-08-23 | 2015-11-26 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための新規フェニル−ピリジン/ピラジンアミド |
EP2914266B1 (en) | 2012-11-01 | 2019-06-19 | University of South Carolina | Cdk8/cdk19 selective inhibitors for use in a method for treating prostate cancer |
US20160000787A1 (en) * | 2013-02-26 | 2016-01-07 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
EP3087080B1 (en) | 2013-12-24 | 2018-11-28 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
US9957251B2 (en) | 2014-04-18 | 2018-05-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP3154952A4 (en) * | 2014-06-10 | 2018-03-14 | University of South Carolina | Methods and compositions for treatment of her-positive cancers |
EP3233086B1 (en) | 2014-12-18 | 2023-02-15 | University of South Carolina | Suppression of neointimal formation following vascular surgery using cdk8 inhibitors |
JP2018516884A (ja) * | 2015-05-08 | 2018-06-28 | プレジデント アンド フェローズ オブ ハーバード カレッジ | コルチスタチン誘導体による治療に対する患者の標的化選択 |
EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
WO2017004411A1 (en) | 2015-07-01 | 2017-01-05 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
MX2018005158A (es) | 2015-11-03 | 2019-05-16 | Lu License Ab | Compuestos para el tratamiento de trastornos hipoproliferativos. |
WO2017091836A1 (en) * | 2015-11-25 | 2017-06-01 | University Of South Carolina | Enhancement of cytarabine activity by inhibiting cdk8/19 |
JP7198489B2 (ja) * | 2016-03-23 | 2023-01-04 | 国立大学法人 岡山大学 | リン酸化sarm1、抗体、sarm1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、sarm1改変体及び使用 |
WO2018027082A1 (en) | 2016-08-03 | 2018-02-08 | The Broad Institute, Inc. | Use of cdk8 inhibitors to treat diseases of inflammation and autoimmunity |
JP7142846B2 (ja) * | 2017-01-30 | 2022-09-28 | 国立大学法人京都大学 | 新規化合物及び制御性t細胞の製造方法 |
WO2018151633A1 (ru) * | 2017-02-20 | 2018-08-23 | Закрытое Акционерное Общество "Биокад" | Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов |
US20220040179A1 (en) * | 2017-02-23 | 2022-02-10 | University Of South Carolina | Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis |
EP3591040A4 (en) | 2017-03-03 | 2020-11-11 | Kyoto University | METHOD FOR PRODUCING PANCREATIC ANALYZER CELLS |
WO2018186366A1 (ja) | 2017-04-03 | 2018-10-11 | 京都薬品工業株式会社 | 新規サイクリン依存性キナーゼ8及び/又は19阻害剤 |
RU2641001C1 (ru) * | 2017-04-03 | 2018-01-15 | Закрытое Акционерное Общество "Биокад" | Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция |
EP3684420A4 (en) * | 2017-09-18 | 2021-06-16 | Chan Zuckerberg Biohub, Inc. | METHOD OF TREATMENT FOR TRIPLE NEGATIVE BREAST CANCER |
JP7285249B2 (ja) | 2017-10-02 | 2023-06-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cdk8/cdk19阻害剤としての新規な[1,6]ナフチリジン化合物及び誘導体 |
RU2763347C2 (ru) * | 2018-03-01 | 2021-12-28 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
US11014906B2 (en) | 2018-08-21 | 2021-05-25 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
AU2020216498A1 (en) | 2019-02-01 | 2021-09-23 | Senex Biotechnology, Inc | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
US20230399607A1 (en) | 2020-11-20 | 2023-12-14 | Orizuru Therapeutics, Inc. | Maturation agent |
TW202246489A (zh) | 2021-02-09 | 2022-12-01 | 日商千紙鶴治療公司 | 成熟化劑 |
US20240180921A1 (en) * | 2021-03-25 | 2024-06-06 | University Of South Carolina | Cdk8/19 inhibitors for the treatment of cytokine storm |
WO2023048275A1 (ja) | 2021-09-27 | 2023-03-30 | 国立大学法人京都大学 | T細胞の製造方法 |
CA3239019A1 (en) | 2021-11-24 | 2023-06-01 | Regcell Co., Ltd. | Human inducibility controllable t-cell and method for preparing same |
WO2023095802A1 (ja) | 2021-11-24 | 2023-06-01 | レグセル株式会社 | T細胞関連疾患を治療または予防するための医薬組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
ATE332896T1 (de) * | 1997-10-27 | 2006-08-15 | Agouron Pharma | 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin- abhängiger kinasen |
US6440959B1 (en) * | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
US20040180848A1 (en) | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
US20040180844A1 (en) | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
WO2004089366A1 (en) * | 2003-04-10 | 2004-10-21 | Pfizer Japan, Inc. | Bicyclic compounds as nr2b receptor antagonists |
CA2652341A1 (en) * | 2006-05-15 | 2007-11-22 | Senex Biotechnology, Inc. | Identification of cdki pathway inhibitors |
US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
-
2013
- 2013-02-01 EA EA201491399A patent/EA028595B1/ru not_active IP Right Cessation
- 2013-02-01 GE GEAP201313566A patent/GEP201706688B/en unknown
- 2013-02-01 EP EP18186536.1A patent/EP3431087A1/en not_active Withdrawn
- 2013-02-01 UA UAA201409643A patent/UA117342C2/uk unknown
- 2013-02-01 JP JP2014555805A patent/JP6193268B2/ja not_active Expired - Fee Related
- 2013-02-01 CN CN201380017703.9A patent/CN104363913B/zh not_active Expired - Fee Related
- 2013-02-01 EA EA201791284A patent/EA032429B1/ru not_active IP Right Cessation
- 2013-02-01 AU AU2013214783A patent/AU2013214783B2/en not_active Ceased
- 2013-02-01 SG SG11201404596UA patent/SG11201404596UA/en unknown
- 2013-02-01 WO PCT/US2013/024515 patent/WO2013116786A1/en active Application Filing
- 2013-02-01 US US13/757,682 patent/US9321737B2/en active Active
- 2013-02-01 KR KR1020147024672A patent/KR20150023223A/ko not_active Application Discontinuation
- 2013-02-01 BR BR112014019052A patent/BR112014019052A8/pt not_active Application Discontinuation
- 2013-02-01 MY MYPI2014002269A patent/MY165446A/en unknown
- 2013-02-01 EP EP13704538.1A patent/EP2809324B1/en not_active Not-in-force
-
2014
- 2014-08-01 CL CL2014002062A patent/CL2014002062A1/es unknown
- 2014-08-18 PH PH12014501862A patent/PH12014501862A1/en unknown
- 2014-08-30 CO CO14191136A patent/CO7151516A2/es unknown
-
2016
- 2016-03-09 US US15/065,083 patent/US10993945B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EA032429B1 (ru) | 2019-05-31 |
EA201491399A1 (ru) | 2015-04-30 |
KR20150023223A (ko) | 2015-03-05 |
EP3431087A1 (en) | 2019-01-23 |
WO2013116786A1 (en) | 2013-08-08 |
US10993945B2 (en) | 2021-05-04 |
US20140038958A1 (en) | 2014-02-06 |
BR112014019052A2 (es) | 2017-06-20 |
MY165446A (en) | 2018-03-22 |
EA028595B1 (ru) | 2017-12-29 |
JP2015506376A (ja) | 2015-03-02 |
EA201791284A1 (ru) | 2017-10-31 |
EP2809324A1 (en) | 2014-12-10 |
US9321737B2 (en) | 2016-04-26 |
CO7151516A2 (es) | 2014-12-29 |
EP2809324B1 (en) | 2018-08-01 |
AU2013214783B2 (en) | 2017-07-06 |
GEP201706688B (en) | 2017-06-26 |
CN104363913B (zh) | 2018-08-21 |
AU2013214783A1 (en) | 2014-08-28 |
US20170071942A1 (en) | 2017-03-16 |
JP6193268B2 (ja) | 2017-09-06 |
PH12014501862A1 (en) | 2014-11-24 |
UA117342C2 (uk) | 2018-07-25 |
CN104363913A (zh) | 2015-02-18 |
SG11201404596UA (en) | 2014-10-30 |
BR112014019052A8 (pt) | 2017-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014002062A1 (es) | Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros. | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
EA201790951A1 (ru) | Производные гидроксиалкилзамещенного фенилтриазола и их применение | |
MX2020010496A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
EA201591145A1 (ru) | Ингибиторы гистондеметилазы | |
CL2017000521A1 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
GT201600123A (es) | Inhibidores de syk | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201692513A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
EA201891526A2 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
CL2016000241A1 (es) | Formulación de inhibidores de la syk. | |
MY188934A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
MD20150085A2 (ro) | Inhibitori ai histon-demetilazelor | |
EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
MX2022010638A (es) | Inhibidores de pde9 para el tratamiento de enfermedades perifericas. | |
BR112016015236A2 (pt) | inibidores de serina/treonina quinase | |
EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения |